Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence study of Mirabegron Sandoz versus Betmiga 50 mg in healthy Thai volunteers under fasting conditions
TCTR20220223005Phase 1Not yet recruiting
- Sponsor
- Novartis
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mirabegron in overactive bladder (OAB) (2 arms), sponsored by Novartis. Primary endpoints: Plasma mirabegron concentration-time profile, AUC0-t and 3 more. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
mirabegron
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on TCTR20220223005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220223005.